Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Balazs Halmos

Showing results (171-180 of 221) with videos related to

Pageof 23
Sort By:
International Journal of Cancer|January 28, 2016
Sunitinib activates Axl signaling in renal cell cancerJohannes C van der Mijn, Henk J Broxterman, Jaco C Knol, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 20, 2022
Crizotinib Has Preclinical Efficacy in Philadelphia-Negative Myeloproliferative NeoplasmsLindsay M Gurska, Rachel Okabe, Alexandra Schurer, et al.
Oncology and Therapy|October 11, 2025
The Phase 2b COPERNICUS Study of Subcutaneous Amivantamab with Lazertinib as First-Line Treatment, or with Chemotherapy as Second-Line Treatment, for EGFR-Mutated Non-Small Cell Lung Cancer: a VodcastBalazs Halmos, Narjust Florez, Sarah Goldberg, et al.
JTO Clinical and Research Reports|September 9, 2022
Characterization of <i>MET</i> Exon 14 Skipping Alterations (in NSCLC) and Identification of Potential Therapeutic Targets Using Whole Transcriptome SequencingSo Yeon Kim, Jun Yin, Stephen Bohlman, et al.
Cancer Cell|February 27, 2022
Impact of COVID-19 on case fatality rate of patients with cancer during the Omicron waveMatthew Lee, Ryann Quinn, Kith Pradhan, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 30, 2020
A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407Luis Paz-Ares, David Vicente, Ali Tafreshi, et al.
JCO Oncology Advances|May 7, 2025
Multiomic Characterization of <i>RCC1</i> and <i>RCC2</i> Expression and Their Association With Molecular Alterations, Immune Phenotypes, and Cancer OutcomesMisako Nagasaka, Brian Warnecke, Sai-Hong Ignatius Ou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 5, 2006
Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinibDavid M Jackman, Beow Y Yeap, Lecia V Sequist, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 3, 2023
Pembrolizumab Plus Chemotherapy in Squamous Non-Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 StudySilvia Novello, Dariusz M Kowalski, Alexander Luft, et al.
Lung Cancer (Amsterdam, Netherlands)|February 14, 2024
Canakinumab in combination with docetaxel compared with docetaxel alone for the treatment of advanced non-small cell lung cancer following platinum-based doublet chemotherapy and immunotherapy (CANOPY-2): A multicenter, randomized, double-blind, phase 3 trialLuis Paz-Ares, Yasushi Goto, Darren Wan-Teck Lim, et al.
Pageof 23

Showing results (171-180 of 221) with videos related to

Sort By:
Pageof 23
International Journal of Cancer|January 28, 2016
Sunitinib activates Axl signaling in renal cell cancerJohannes C van der Mijn, Henk J Broxterman, Jaco C Knol, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 20, 2022
Crizotinib Has Preclinical Efficacy in Philadelphia-Negative Myeloproliferative NeoplasmsLindsay M Gurska, Rachel Okabe, Alexandra Schurer, et al.
Oncology and Therapy|October 11, 2025
The Phase 2b COPERNICUS Study of Subcutaneous Amivantamab with Lazertinib as First-Line Treatment, or with Chemotherapy as Second-Line Treatment, for EGFR-Mutated Non-Small Cell Lung Cancer: a VodcastBalazs Halmos, Narjust Florez, Sarah Goldberg, et al.
JTO Clinical and Research Reports|September 9, 2022
Characterization of <i>MET</i> Exon 14 Skipping Alterations (in NSCLC) and Identification of Potential Therapeutic Targets Using Whole Transcriptome SequencingSo Yeon Kim, Jun Yin, Stephen Bohlman, et al.
Cancer Cell|February 27, 2022
Impact of COVID-19 on case fatality rate of patients with cancer during the Omicron waveMatthew Lee, Ryann Quinn, Kith Pradhan, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 30, 2020
A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407Luis Paz-Ares, David Vicente, Ali Tafreshi, et al.
JCO Oncology Advances|May 7, 2025
Multiomic Characterization of <i>RCC1</i> and <i>RCC2</i> Expression and Their Association With Molecular Alterations, Immune Phenotypes, and Cancer OutcomesMisako Nagasaka, Brian Warnecke, Sai-Hong Ignatius Ou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 5, 2006
Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinibDavid M Jackman, Beow Y Yeap, Lecia V Sequist, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 3, 2023
Pembrolizumab Plus Chemotherapy in Squamous Non-Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 StudySilvia Novello, Dariusz M Kowalski, Alexander Luft, et al.
Lung Cancer (Amsterdam, Netherlands)|February 14, 2024
Canakinumab in combination with docetaxel compared with docetaxel alone for the treatment of advanced non-small cell lung cancer following platinum-based doublet chemotherapy and immunotherapy (CANOPY-2): A multicenter, randomized, double-blind, phase 3 trialLuis Paz-Ares, Yasushi Goto, Darren Wan-Teck Lim, et al.
Pageof 23